BioNTech Widens Board and Sharpens Oncology Focus as Pumitamig Heads to ASCO Under the Spotlight

BioNTech appoints two pharma heavyweights to its board, prepares for pivotal pumitamig Phase 2 data at ASCO, and advances pipeline with 15 Phase 3 programs by 2026 despite a widened Q1 net loss of €531.9M.

BioNTech has expanded its supervisory board from six to eight members, adding two pharmaceutical heavyweights with deep oncology and commercial expertise just as the company’s pipeline enters a make-or-break phase. Professor Iris Löw-Friedrich and Dr. Susanne Schaffert join a panel that now looks markedly different from the one that steered the COVID-vaccine windfall. Helmut Jeggle takes the chairmanship, and several incumbents had their mandates renewed. The overhaul, approved at the annual general meeting with 92% of capital represented, is far from cosmetic: it signals that management expects clinical development, regulatory filings, and eventual market launches to run in tighter unison from here.

The immediate test arrives at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago on 29 May, where BioNTech will present Phase?2 data for pumitamig, its PD-L1/VEGF-A bispecific antibody. Abstracts were released on 21 May, giving the market a first glimpse. Pumitamig is being co-developed with Bristol Myers Squibb and is evaluated head-to-head against Merck’s Keytruda (pembrolizumab) plus chemotherapy in first-line non-small cell lung cancer under the ROSETTA-Lung-02 trial. Keytruda is the gold standard in this setting, so convincing efficacy would carry weight; underwhelming numbers would revive doubts about the speed at which BioNTech can create value from its oncology pipeline. The company is not alone in this class — Pfizer and 3SBio also have a competing bispecific, and real-time benchmarking at ASCO will sharpen the competitive picture.

Beyond lung cancer, pumitamig is being investigated across several solid tumours: first-line hepatocellular carcinoma, second-line glioblastoma, first-line pancreatic cancer, and first-line renal cell carcinoma, in both monotherapy and combination settings. The Phase?2/3 study is already recruiting for its Phase?3 portion. BioNTech intends to have 15 Phase?3 programmes running by 2026, having launched six additional late-stage trials this year alone. The current year also holds seven late-stage data readouts, with pumitamig the most prominent.

Another key pipeline asset is trastuzumab pamirtecan (BNT323), an ADC partnered with DualityBio. Based on Phase?2 data from April showing a confirmed objective response rate of 49.3% in patients previously treated with checkpoint inhibitors (47.9% across the full group) and a median progression-free survival of 8.1 months, the company plans to submit a BLA in the US in 2026, subject to FDA feedback. The drug already holds Fast Track and Breakthrough Therapy designations for endometrial cancer. In the HER2 IHC3+ subgroup, the response rate exceeded 70%.

The financial backdrop is demanding. BioNTech posted a first-quarter net loss of €531.9?million, 28% wider than a year ago, as revenue slumped 35% to €118.1?million. The loss per share came in at €2.10. Management’s non-IFRS revenue guidance for 2026 stands at €2.0?2.3?billion, with adjusted R&D costs of €2.2?2.5?billion and adjusted SG&A of €700?800?million. Despite the bleeding, the balance sheet remains fortress-like: €19.6?billion in cash and a $1.0?billion share buyback programme running over twelve months. A separate deal with BMS on pumitamig brought an upfront and non-contingent payment of $3.5?billion, plus up to $7.6?billion in milestones.

Cost discipline is accelerating. BioNTech will close its sites in Idar-Oberstein, Marburg and Tübingen by the end of next year, and wind down manufacturing in Singapore. From 2029, the company expects recurring annual savings of roughly €500?million. The restructuring is part of a broader pivot from a pandemic-era production machine to a sustainable oncology business.

The stock fared better on Friday, climbing 3.51% to €81.05, almost exactly at its 50?day moving average of €80.99. That partial recovery came after a bruising month: the shares closed Thursday at €78.30, down 16.52% over the preceding four weeks and trading 9.53% below the 200?day average. Analyst views are split widely — Canaccord maintains a “Buy” with a $158 target, while Leerink is more cautious at $94, reflecting how much the valuation now hinges on clinical outcomes.

With ASCO kicking off and a second?quarter earnings report looming, the next few weeks will show whether BioNTech can translate its pipeline breadth into convincing data. Beyond pumitamig, investors will watch for updates on gotistobart in non?small cell lung cancer, BNT113 in head?and?neck tumours, and additional ADC programmes later in the year. The board expansion signals readiness for the execution phase; the ASCO dataset will be the first real test.